Saturday, July 11, 2026

Drug profile · INN

lincomycin hydrochloride

lincomycin hydrochloride (LINCOMYCIN HCL) is a 70s ribosome inhibitor. Route of administration: injection. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — lincomycin hydrochloride
US status
approved
Class
Route
INJECTION
Patents
0
Programs
0
Data quality
0.84

Quick answer

lincomycin hydrochloride (LINCOMYCIN HCL) is a 70s ribosome inhibitor. Route of administration: injection. Current US regulatory status: approved.

Key facts

INN lincomycin hydrochloride
Brand LINCOMYCIN HCL
Mechanism 70S ribosome inhibitor
Target 70S ribosome
Route INJECTION
Formulation INJECTABLE

Mechanism of action

70S ribosome inhibitor

Primary target: 70S ribosome

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. azithromycin Bacterial 70S ribosome inhibitor
  2. chloramphenicol Bacterial 70S ribosome inhibitor
  3. clarithromycin Bacterial 70S ribosome inhibitor
  4. clindamycin hydrochloride Bacterial 70S ribosome inhibitor
  5. clindamycin palmitate hydrochloride Bacterial 70S ribosome inhibitor
  6. clindamycin phosphate Bacterial 70S ribosome inhibitor

Frequently asked questions

What is lincomycin hydrochloride?

lincomycin hydrochloride (LINCOMYCIN HCL) is a 70s ribosome inhibitor. Route of administration: injection. Current US regulatory status: approved.

What is the brand name for lincomycin hydrochloride?

LINCOMYCIN HCL is a marketed brand name for lincomycin hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of lincomycin hydrochloride?

lincomycin hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.